Key points are not available for this paper at this time.
Radiopharmaceutical therapy (RPT) is now widely recognized as an effective modality transforming cancer management. Within the last decade, prospective clinical trials using 177Lu-labeled therapies have led to the widespread adoption of 177LuLu-DOTA-octreotate therapy for patients with
Kong et al. (Thu,) studied this question.